I like to stay up to date on breast cancer research and new drug trials. I want to start highlighting important ones on my blog so that I have a repository of research that applies to me. I’ll keep adding to this blog post when I find new journal articles or trials that might apply to me.
| Title | Journal, issue, and date | Notes |
| Overall survival is the lowest among young women with postpartum breast cancer | European Journal of Cancer; Volume 168, June 2022, Pages 119-127 | Overall survival for those with PPBC, dx <35 years of age (Stage I) is significantly worse than those that have never had a child or those that are 5+ years out from their most recent pregnancy. I was dx with Stage I BC at the age of 31, and 18 months postpartum. I was dx with Stage IV at the age of 33, 4 years postpartum. These factors put me in the highest risk category for worst overall survival at 15 years post diagnosis. |
| Long-term disease control with capecitabine in advanced breast cancer | Journal of Clinical Oncology; Volume 35, Issue 15 Supplement, May 30, 2017, | Capecitabine can be administered at lower dosages than what is approved and will have the same progression free survival (PFS) outcomes as the higher doses. Median age for study was 64 years old. 6.9 months for PFS. |
| Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study | Oncology Research and Treatment; Volume 37, October 2014, Pages 748-755 | PFS 6.81 (6.32-7.63) and those with Hand Foot Syndrome faired better at 8.4 months (7.5-9.2). |
Hannah in CancerLand 
As I have always seen, you are a TOTAL SURVIVOR! So glad Ollie can enjoy your family lately. We are indeed blessed to have you guys across the street. Hang touch Hannah! You are amazing and so glad you are kicking cancer’s butt.
LikeLike
That’s “hang tough”, not hang touch 🙂
LikeLike